Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Plantarum in Treating Psoriasis
NCT07194200Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Countries
- 1
- Sponsor
- Shenzhen People's Hospital
- Modality
- Live Biotherapeutic Products
- Conditions
- psoriasis
01
Overview
Phase 2, randomised, double-blind trial of lactobacillus plantarum in psoriasis (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Transepidermal Water Loss at 8 weeks, General appearance photography at 8 weeks and 3 more. Started Dec 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Experimental Group
Lactobacillus plantarum solution
Control Group
Inactivated Lactobacillus plantarum solution
03
Who it enrols
Patients aged 18-60 with psoriasis (PASI < 10), no use of medications within 6 months, and no other inflammatory/immune skin diseases or local infections.
04
Endpoints
Primary
Transepidermal Water Loss
General appearance photography
Dermoscopic photography
Completion of self-assessment questionnaires
Adverse reactions
Beyond the preview
Go deeper on NCT07194200.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194200.